نتائج البحث - Carmelo Nucera

  • يعرض 1 - 12 نتائج من 12
تنقيح النتائج
  1. 1
    Personalized Therapy in Patients With Anaplastic Thyroid Cancer: Targeting Genetic and Epigenetic Alterations

    Personalized Therapy in Patients With Anaplastic Thyroid Cancer: Targeting Genetic and Epigenetic Alterations حسب Neal Smith, Carmelo Nucera

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression

    BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression حسب Carmelo Nucera, Jack Lawler, Sareh Parangi

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A Novel Orthotopic Mouse Model of Human Anaplastic Thyroid Carcinoma

    A Novel Orthotopic Mouse Model of Human Anaplastic Thyroid Carcinoma حسب Carmelo Nucera, Matthew A. Nehs, Michal Mekel, Xuefeng Zhang, Richard A. Hodin, Jack Lawler, Vânia Nosé, Sareh Parangi

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer

    Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer حسب Matthew A. Nehs, Carmelo Nucera, Sushruta S. Nagarkatti, Peter M. Sadow, Dieter Morales-García, Richard A. Hodin, Sareh Parangi

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E

    Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E حسب Zeus A. Antonello, Nancy Hsu, Manoj Bhasin, Giovanni Roti, Mukta Joshi, Paul Van Hummelen, Emily Ye, Agnes S. Lo, S. Ananth Karumanchi, Christine R. Bryke, Carmelo Nucera

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer حسب Carmelo Nucera, Matthew A. Nehs, Sushruta S. Nagarkatti, Peter M. Sadow, Michal Mekel, Andrew H. Fischer, Paul Lin, Gideon Bollag, Jack Lawler, Richard A. Hodin, Sareh Parangi

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    <i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma

    <i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma حسب Carmelo Nucera, Jérôme Eeckhoute, Stephen P. Finn, Jason S. Carroll, Azra H. Ligon, Carmen Priolo, Guido Fadda, Mary Toner, Orla Sheils, Marco Attard, Alfredo Pontecorvi, Vânia Nosé, Massimo Loda, Myles Brown

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2

    SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2 حسب Shavali Shaik, Carmelo Nucera, Hiroyuki Inuzuka, Daming Gao, Maija Garnaas, Gregory M. Frechette, Lauren Harris, Lixin Wan, Hidefumi Fukushima, Amjad Husain, Vânia Nosé, Guido Fadda, Peter M. Sadow, Wolfram Goessling, Trista E. North, Jack Lawler, Wenyi Wei

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    B-Raf<sup>V600E</sup>and thrombospondin-1 promote thyroid cancer progression

    B-Raf<sup>V600E</sup>and thrombospondin-1 promote thyroid cancer progression حسب Carmelo Nucera, Alessandro Porrello, Zeus A. Antonello, Michal Mekel, Matthew A. Nehs, Thomas J. Giordano, Damien Gerald, Laura E. Benjamin, Carmen Priolo, Efisio Puxeddu, Stephen P. Finn, Barbara Jarząb, Richard A. Hodin, Alfredo Pontecorvi, Vânia Nosé, Jack Lawler, Sareh Parangi

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis

    Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis حسب Alessandro Prete, Agnes S. Lo, Peter M. Sadow, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John G. Clohessy, Ann M. Dvořàk, Tracey Sciuto, Manoj Bhasin, Joanne E. Murphy-Ullrich, Jack Lawler, S. Ananth Karumanchi, Carmelo Nucera

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclinical model

    Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclin... حسب Mark Duquette, Peter M. Sadow, Amjad Husain, Jennifer N. Sims, Zeus A. Antonello, Andrew H. Fischer, Song Chen, Elena Castellanos-Rizaldos, G. Mike Makrigiorgos, Junichi Kurebayashi, Vânia Nosé, Paul Van Hummelen, Roderick T. Bronson, Michelle Vinco, Thomas J. Giordano, Dora Dias‐Santagata, Pier Paolo Pandolfi, Carmelo Nucera

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    The landscape of somatic copy-number alteration across human cancers

    The landscape of somatic copy-number alteration across human cancers حسب Rameen Beroukhim, Craig H. Mermel, Dale Porter, Wei Guo, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S. Boehm, Jennifer Dobson, Mitsuyoshi Urashima, Kevin T. Mc Henry, Reid M. Pinchback, Azra H. Ligon, Yoon‐Jae Cho, Leila Haery, Heidi Greulich, Michael Reich, Wendy Winckler, Michael S. Lawrence, Barbara A. Weir, Kumiko Tanaka, Derek Y. Chiang, Adam J. Bass, Alice Loo, Carter Hoffman, John R. Prensner, Ted Liefeld, Qing Gao, Derek Yecies, Sabina Signoretti, Elizabeth A. Maher, Frederic J. Kaye, Hidefumi Sasaki, Joel E. Tepper, Jonathan A. Fletcher, Josep Tabernero, José Baselga, Ming‐Sound Tsao, Francesca Demichelis, Mark A. Rubin, Pasi A. Jänne, Mark J. Daly, Carmelo Nucera, Ross L. Levine, Benjamin L. Ebert, Stacey Gabriel, Anil K. Rustgi, Cristina R. Antonescu, Marc Ladanyi, Anthony Letai, Levi A. Garraway, Massimo Loda, David G. Beer, Lawrence D. True, Aikou Okamoto, Scott L. Pomeroy, Samuel Singer, Todd R. Golub, Eric S. Lander, Gad Getz, William R. Sellers, Matthew Meyerson

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: